What is Guizhou Xinbang Pharmaceutical Co., Ltd.'s (002390.SZ) StockRank?

MoatMap's StockRank for Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) is 81/100, with a Strong Buy signal. This is a composite score combining Quality (52), Value (63), and Momentum (53) factor ranks across MoatMap's 20,000+ stock universe.

Does Guizhou Xinbang Pharmaceutical Co., Ltd. have an economic moat?

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Guizhou Xinbang Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Guizhou Xinbang Pharmaceutical Co., Ltd. in?

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

002390.SZ

STRONG BUYREMOVE

Guizhou Xinbang Pharmaceutical Co., Ltd. · Healthcare · China · $870M · Avg Vol: $10M/d

StockRank

P/E (TTM)

40.9x

ROE

2.9%

D/E

0.1x

Dividend %

3.1%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Guizhou Xinbang Pharmaceutical is a Chinese healthcare provider and hospital operator. It does not possess the global scale, regulatory moats, or pricing power of a high-conviction CDMO player.

COMPANY DESCRIPTION

Guizhou Xinbang Pharmaceutical Co., Ltd. operates a vertically integrated healthcare business encompassing pharmaceutical manufacturing, medical distribution, and hospital management. The company holds a dominant position in the regional healthcare market of Guizhou province, operating a network of private hospitals and medical centers. Its integrated model allows it to capture value across the entire healthcare delivery chain, from drug supply to patient care.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	956M	938M	955M	892M	—	-2.3%
EPS	—	0.02	0.02	0.01	0.01	-19.2%
Shares	2.0B	1.9B	1.9B	1.9B	—	-4.1%
Debt	205M	202M	121M	115M	—	-17.6%
Equity	978M	1.0B	1.0B	992M	—	0.5%
Op CF	—	68M	87M	117M	94M	11.5%
Inv CF	—	-110M	-17M	7M	-17M	—
Fin CF	—	-135M	-28M	-134M	-47M	—

PRICE (1M)-15.0%

SMA 50SMA 200

$0.42

RSI (14)

29.8

52W High

$0.60

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC (ROA)

2.2%*48.9

ROE

2.9%50.6

GP/Assets

—N/A

Op. Margin

6.1%57.6

FCF/Assets

—N/A

Piotroski

—83.4

Int. Cover

—N/A

D/E Ratio

0.06x72.6

Current Ratio

3.50x58.9

Value

P/E (TTM)

40.9x26.0

EV/EBITDA

10.1x42.1

P/FCF

54.0x87.6

P/B

0.8x84.3

P/S

1.0x83.1

Div Yield

3.1%71.8

Momentum

52W High %

69%55.1

RS 6M

-35%34.3

SMA 50/200

0.92x39.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—90.4

Q Growth

18%61.5

FUNDAMENTALS

Market Cap

$870M

P/E (Forward)

11.9x

Gross Margin

17.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002390.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
002390.SZ	Guizhou Xinbang Pharmaceutical Co., Ltd.(you)	$870M	81	STRONG BUY
603367.SS	Cisen Pharmaceutical Co., Ltd.	$934M	81	STRONG BUY
002349.SZ	Jinghua Pharmaceutical Group Co., Ltd.	$866M	85	STRONG BUY
600664.SS	Harbin Pharmaceutical Group Co., Ltd.	$1.3B	81	STRONG BUY
603676.SS	Tibet Weixinkang Medicine Co., Ltd.	$594M	83	STRONG BUY
002437.SZ	HARBIN GLORIA PHARMACEUTICALS Co., LTD	$975M	73	BUY
300705.SZ	Hunan Jiudian Pharmaceutical Co., Ltd.	$869M	70	BUY
6998.HK	Edding Genor Group Holdings Limited	$509M	81	STRONG BUY
600976.SS	Jianmin Pharmaceutical Group Co.,Ltd.	$690M	87	STRONG BUY
603439.SS	Guizhou Sanli Pharmaceutical Co.,Ltd	$984M	70	BUY

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) — Stock Score Summary

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) has a MoatMap StockRank of 81/100 based on Quality (52/100), Value (63/100), and Momentum (53/100) factor scores. The current signal is STRONG BUY. Guizhou Xinbang Pharmaceutical is a Chinese healthcare provider and hospital operator. It does not possess the global scale, regulatory moats, or pricing power of a high-conviction CDMO player.

Key Financial Metrics

Price	$0.42
Market Cap	$870M
P/E (TTM)	40.86
P/E (Forward)	11.92
Price/Book	0.79
Return on Equity	2.9%
Debt/Equity	6.01
Gross Margin	17.5%
Operating Margin	6.1%
Revenue Growth	-12.3%
Dividend Yield	3.1%
Free Cash Flow	$16M

Guizhou Xinbang Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Guizhou Xinbang Pharmaceutical Co., Ltd.’s (002390.SZ) StockRank?: MoatMap’s StockRank for Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) is 81/100, with a Strong Buy signal. It is a composite of Quality (52), Value (63), and Momentum (53) factor ranks across MoatMap’s 20,000+ stock universe.
Does Guizhou Xinbang Pharmaceutical Co., Ltd. have an economic moat?: Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Guizhou Xinbang Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Guizhou Xinbang Pharmaceutical Co., Ltd. in?: Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).